* Aim to be a respected global company dedicated on injectable drugs.
* Focused on development & manufacture of high-quality and effective drugs for worldwide healthcare market.
* Dynamic and energetic culture of working on customer’s needs by offering flexible and professional service.
* As MHRA approved and an EU releaser, own brand drug supplied to more than 1000 EU hospitals.
* London subsidiary is responsible for international sales and registration, established business partnerships in more than 80 countries with ongoing product registrations.
Milestone
Oct. 2010
Established by a group of international pharmaceutical veterans
Sep. 2012
Manufacturing Site completion (construction, commissioning)
Sep. 2013
First validation batches
April 2014
MHRA GMP Approval and in Oct 2014, Chinese GMP approval
July 2015
Irinotecan Injection launched in UK supplying to more than 700 top EU hospitals
March 2016
Docetaxel, Doxorubicin and Zoledronic Acid Injection launched in EU
August 2017
Passed MHRA GMP Re-audit
Oct. 2010
Established by a group of international pharmaceutical veterans
Sep. 2012
Manufacturing Site completion (construction, commissioning)
Sep. 2013
First validation batches
April 2014
MHRA GMP Approval and in Oct 2014, Chinese GMP approval
July 2015
Irinotecan Injection launched in UK supplying to more than 700 top EU hospitals
March 2016
Docetaxel, Doxorubicin and Zoledronic Acid Injection launched in EU
